Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the availability of Enhertu for the treatment of (a) HER2-positive and (b) HER2-low breast cancer.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Excellence (NICE) is the independent body that makes recommendations for the National Health Service on whether new licensed medicines should be routinely funded by the NHS based on an evaluation of a treatment’s costs and benefits. These are very difficult decisions to make, and it is important that they are made independently and based on the available evidence. The NHS in England is legally required to fund medicines recommended by NICE.
NICE has been able to recommend Enhertu for treating HER2-positive unresectable or metastatic breast cancer after one or more anti-HER2 treatments and for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies. Enhertu is now available for NHS patients in line with NICE’s recommendations.
On 29 July 2024, NICE published final guidance on Enhertu for use in the treatment of HER2-low metastatic breast cancer, and it was unable to recommend this life-extending treatment. The only obstacle to access for NHS patients to Enhertu is price, and my Rt. Hon. Friend, the Secretary of State for Health and Social Care, met the manufacturers of Enhertu, AstraZeneca and Daiichi Sankyo to encourage them to re-enter discussions with NHS England with a view to reaching a price at which NICE would be able to recommend Enhertu.
However, despite NICE and NHS England offering unprecedented flexibility, the companies were unable to offer Enhertu at a cost-effective price. NICE’s guidance will therefore remain unchanged for the moment. However, NICE remains open to being as flexible as possible with commercial partners and are willing to enter into a new NICE appraisal if there is movement on pricing.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to help prevent patients being treated in (a) corridors, (b) converted office spaces, (c) gyms and (d) other inappropriate spaces in winter 2025-26.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
We are doing everything we can as fast as we can to tackle and eliminate corridor care. The Government is determined to get the National Health Service back on its feet, so patients can be treated with dignity.
Our Urgent and Emergency Care Plan, published in June 2025, set out the steps we are taking to ensure that patients will receive better, faster, and more appropriate emergency care this winter, backed by a total of nearly £450 million of funding. This includes a commitment to publish data on the prevalence of corridor care.
We have been taking key steps to ensure that the health service is prepared for the colder months. This includes taking actions to try to reduce the demand pressure on accident and emergency departments, increase vaccination rates, and offer health checks to the most vulnerable, as well as stress-testing integrated care board and trust winter plans to confirm they are able to meet demand and support patient flow.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what the conclusive findings were of the Government-funded psilocybin trial that concluded in February 2024.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The National Institute for Health and Care Research (NIHR) Clinician Scientist Fellowship titled ‘A Feasibility RCT of Single-Dose Psilocybin in Unipolar Depressive Disorder Resistant to Standard Treatments’ is shown on the NIHR Funding and Awards website as concluding in February 2024. The progress of this award was significantly delayed by the COVID-19 pandemic. The results are therefore not yet available and are due to be released in 2026.
The main aim of this award is to investigate the feasibility of conducting a trial in this patient group and to contribute towards the design of a more definitive study. The award has resulted in the creation of the Psychoactive Trials Group at King’s College London, which is one of the world’s most experienced clinical research teams in this emerging area of treatment.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with Baroness Casey on how sector stakeholders can engage with the commission on adult social care.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
My Rt Hon. Friend, the Secretary of State for Health and Social Care, engages with Baroness Louise Casey regularly on a number of issues, including adult social care.
On 8 September, my Rt. Hon. Friend attended cross-party discussions, chaired by Baroness Casey, with representatives from political parties.
Over the coming months, the commission will start a national conversation by inviting members of the public, people drawing on care and support, and organisations to submit evidence and to share their stories and ideas for improvement of the existing adult social care system. The commission will set out more details in due course.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential impact of adult social care on supporting people of working age into the labour market.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
Adult social care plays a vital role and directly supports people of working age to enter, remain in, or return to employment, and ultimately to maintain people’s independence. By ensuring individuals receive the right care in the right place at the right time, they are better able to contribute to society through employment, volunteering, or other forms of participation. To support working aged people into the labour market, earnings from employment are specifically disregarded from financial assessments, with further information available at the following link:
https://www.legislation.gov.uk/uksi/2014/2672/regulation/14
This is to ensure that working aged adults who are in employment are able to retain their earnings in full, and supplement their income, in addition to retaining the Minimum Income Guarantee (MIG) after being charged for their social care.
The Government also recognises the importance of supporting unpaid carers. Access to appropriate support, such as respite care, is important to help carers maintain their own wellbeing and avoid burnout, which can otherwise lead to withdrawal from the workforce. To support this, we are committed to reviewing the implementation of Carer’s Leave and examining the benefits of introducing paid Carer’s Leave.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to (a) help ensure that NHS skin cancer referrals are completed within the 14-day target and (b) address the backlog in Farnham and Bordon constituency.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department is supporting the National Health Service in taking steps to reduce the time taken from referral to diagnosis of cancer, including skin cancer.
As a first step, NHS England published guidance for local health and care systems and providers across England to achieve the Faster Diagnosis Standard (FDS) titled Implementing a timed skin cancer diagnostic pathway. The FDS pathway ensures patients receive a diagnosis of cancer, or rule out cancer, within 28 days of referral, as per the cancer waiting time standard.
Since 2023/24, NHS England has been rolling out teledermatology services, which allow virtual reviews of dermoscopic images, to support achieving faster diagnosis. In providers where these have been fully implemented, improvements in workforce capacity have been seen, in some cases doubling the number of patients that can be reviewed per clinic, and improving FDS performance.
Additionally, NHS England’s Getting It Right First Time (GIRFT) national report has provided recommendations to encourage the wider use of technology to ensure skin cancer patients get faster and more equitable access to care.
In July, a report was published by NHS Frimley Integrated Care Board (ICB), which covers services in Farham and Bordon constituency, providing an update on elective care and cancer backlogs across the ICB. The report included steps taken to address the backlog, which included:
- the trust holding weekly meetings to review long waiters, cancer patients, validation and prioritisation;
- the use of more technology to improve appointments;
- supporting patients while they wait; and
- opening a new community diagnostic centre.
The report is available at the following link:
Finally, the forthcoming National Cancer Plan will have patients at its heart and will cover the entirety of a pathway including from referral to diagnosis.
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what funding has been allocated under the NHS 10-Year Plan to support cardiac screening programmes for young people.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
In the United Kingdom, national screening programmes are introduced based on the recommendations of the UK National Screening Committee (UK NSC), an independent scientific advisory committee which advises ministers and the National Health Service in all four countries on all aspects of population and targeted screening and which supports implementation.
The UK NSC last reviewed screening for sudden cardiac death in people under the age of 39 years old in 2019, and concluded that population screening should not be offered. Further information is available at the following link:
https://view-health-screening-recommendations.service.gov.uk/sudden-cardiac-death/
The UK NSC is currently examining the evidence for this condition and will open a public consultation to seek comments from members of the public and stakeholders on this in due course. Further information, including on how to keep up to date on the work of the UK NSC, is available at the following link:
https://www.gov.uk/government/organisations/uk-national-screening-committee
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of proactive cardiac screening on preventing sudden cardiac deaths among young people.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
In the United Kingdom, national screening programmes are introduced based on the recommendations of the UK National Screening Committee (UK NSC), an independent scientific advisory committee which advises ministers and the National Health Service in all four countries on all aspects of population and targeted screening and which supports implementation.
The UK NSC last reviewed screening for sudden cardiac death in people under the age of 39 years old in 2019, and concluded that population screening should not be offered. Further information is available at the following link:
https://view-health-screening-recommendations.service.gov.uk/sudden-cardiac-death/
The UK NSC is currently examining the evidence for this condition and will open a public consultation to seek comments from members of the public and stakeholders on this in due course. Further information, including on how to keep up to date on the work of the UK NSC, is available at the following link:
https://www.gov.uk/government/organisations/uk-national-screening-committee
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department is taking to increase access to cardiac screening for young people with no prior symptoms of heart conditions.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
In the United Kingdom, national screening programmes are introduced based on the recommendations of the UK National Screening Committee (UK NSC), an independent scientific advisory committee which advises ministers and the National Health Service in all four countries on all aspects of population and targeted screening and which supports implementation.
The UK NSC last reviewed screening for sudden cardiac death in people under the age of 39 years old in 2019, and concluded that population screening should not be offered. Further information is available at the following link:
https://view-health-screening-recommendations.service.gov.uk/sudden-cardiac-death/
The UK NSC is currently examining the evidence for this condition and will open a public consultation to seek comments from members of the public and stakeholders on this in due course. Further information, including on how to keep up to date on the work of the UK NSC, is available at the following link:
https://www.gov.uk/government/organisations/uk-national-screening-committee
Asked by: Gregory Stafford (Conservative - Farnham and Bordon)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to support wider access to cardiac screening provided by (a) Cardiac Risk in the Young and (b) other charities.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
In the United Kingdom, national screening programmes are introduced based on the recommendations of the UK National Screening Committee (UK NSC), an independent scientific advisory committee which advises ministers and the National Health Service in all four countries on all aspects of population and targeted screening and which supports implementation.
The UK NSC last reviewed screening for sudden cardiac death in people under the age of 39 years old in 2019, and concluded that population screening should not be offered. Further information is available at the following link:
https://view-health-screening-recommendations.service.gov.uk/sudden-cardiac-death/
The UK NSC is currently examining the evidence for this condition and will open a public consultation to seek comments from members of the public and stakeholders on this in due course. Further information, including on how to keep up to date on the work of the UK NSC, is available at the following link:
https://www.gov.uk/government/organisations/uk-national-screening-committee